#GLP1 #Inflammation #Metabolism #Biotech #HealthcareInnovation #DrugMechanism #ChronicDisease GLP-1s & Bone Loss Recent data from early 2026 suggests that while GLP-1 receptor agonists (like semaglutide and tirzepatide) are revolutionary for weight management, they do present a real "skeletal cost" that requires proactive management
PRP is also not a one-time treatment
Ethics declarations Competing interests We disclose the following potential conflicts of interest regarding the publication of this manuscript: This research was partly funded by Cleara Biotech
My bottom line: a balanced view Thoughtful use, open communication and routine monitoring keep B12 injections useful and safe
Lauren A Jones, Daniel I Brierley, GLP-1 and the Neurobiology of Eating Control: Recent Advances, Endocrinology , Volume 166, Issue 2, February 2025, bqae167, Gabe MBN, Breitschaft A, Knop FK, Hansen MR, Kirkeby K, Rathor N, Adrian CL